NextTrip Stock Price, News & Analysis

NextTrip, Inc. (NASDAQ:NTRP), a travel technology company, has received a notification from Nasdaq on July 17, 2024, stating its continued noncompliance with Listing Rule 5250(c)(1). The company has failed to timely file its Quarterly Report on Form 10-Q for the quarter ended May 31, 2024, and its Annual Report on Form 10-K for the year ended February 29, 2024.

NextTrip has until August 16, 2024, to either file the delinquent reports or submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant an extension until December 10, 2024. Failure to comply could result in delisting from The Nasdaq Capital Market, subject to appeal. The company intends to file the reports or submit a compliance plan by the deadline.

NextTrip (NASDAQ:NTRP) has partnered with Dooya Media Group to launch Compass.TV, a travel discovery channel and app set to debut in September 2024. This innovative FAST (free ad-supported streaming television) channel aims to revolutionize the tourism industry by offering:

1. Virtual exploration of destinations through experienced travelers and local insiders
2. Spotlights on accommodations, local foods, and must-visit locations
3. Seamless content-to-commerce integration using NextTrip's Booking Engine
4. Curated and personalized content for travelers and enthusiasts
5. High-quality influencer-led content including travel documentaries and virtual tours

Compass.TV will be available on iOS, Android, web browsers, and later on platforms like Roku, Apple TV, and Amazon Fire TV. This partnership aims to set a new standard in travel discovery and engagement while driving advertising revenue and bookings.

NextTrip has unveiled FlexPay, a proprietary technology for their travel booking site, which introduces flexible payment options. FlexPay allows customers to pay for accommodations over time through interest-free installments and does not require credit checks. This feature aims to capitalize on the growing trend of 'buy now, pay later' services, which represented 4% of 2021 e-commerce transactions in Canada and the US and is expected to grow to 9% by 2025. FlexPay is integrated into the booking process and will be used in social media travel campaigns and direct-to-consumer marketing to drive sales and conversion rates. NextTrip anticipates that FlexPay will make travel more affordable and flexible, particularly appealing to younger travelers, and enhance marketing efforts throughout the year.

NextTrip, a travel technology company, has received a notification from Nasdaq indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its annual report on Form 10-K for the fiscal year ending February 29, 2024. The company now has 60 days to submit a compliance plan to Nasdaq. If accepted, NextTrip may have until December 10, 2024, to meet the filing requirements. Further details are available in the company's Form 8-K filed with the SEC.

Synaptogenix, Inc. (OTC: SNPX) has announced the receipt of its first batch of synthetic Bryostatin under an exclusive licensing agreement with Stanford University. This development will enable the company to expand its research and conduct trials for various neurodegenerative disorders including Alzheimer's, Multiple Sclerosis, and Parkinson's disease. The synthetic supply addresses the need for increased availability, crucial for the development of orally deliverable compounds. The company aims to complement ongoing Phase 2 trials in Alzheimer's Disease with additional studies utilizing the new supply.

Synaptogenix, Inc. (OTC: SNPX) has announced the receipt of its first synthetic Bryostatin batch, obtained through an exclusive licensing agreement with Stanford University. This development marks a significant milestone, allowing the company to expand its research initiatives, particularly for an orally deliverable compound. The increased supply will facilitate new clinical trials for various neurodegenerative disorders including Alzheimer's, Multiple Sclerosis, and Parkinson's. Synaptogenix's existing studies include Bryostatin-1, which has a notable safety profile from prior cancer research.

Neurotrope and Metuchen Pharmaceuticals have completed their merger, creating a new public holding company, Petros Pharmaceuticals, trading under the symbol PTPI. Neurotrope shareholders will own approximately 49% and Metuchen shareholders 51% of Petros. This merger includes a spin-off of Neurotrope's existing assets and liabilities. Petros aims to enhance the commercialization of its lead product, Stendra®, an FDA-approved erectile dysfunction treatment, while exploring its potential shift to over-the-counter status. The merger intends to create long-term value for stakeholders.

Neurotrope, Inc. (NASDAQ: NTRP) announced its Board of Directors approved the spin-off of its subsidiary, Neurotrope Bioscience, Inc. (NBI). Shareholders of record on November 30, 2020, will receive one share of NBI for every five shares of Neurotrope held on December 7, 2020. This follows a planned merger with Metuchen Pharmaceuticals, forming a new company named Petros Pharmaceuticals, Inc. The distribution is taxable and subject to specific conditions, including shareholder approval of the merger set for November 25, 2020.